Showing items 1 - 3 of 3

Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study

- Shapiro, Jeremy D., Thavaneswaran, Subotheni, Tebbutt, Niall C., Price, Timothy J., Khasraw, Mustafa, Van Hazel, Guy A., Waring, Paul M., Tejpar, Sabine, Simes, John, Gebski, Val J., Desai, Jayesh, Segelov, Eva, Underhill, Craig R., Robledo, Kristy P., Karapetis, Chistos S., Day, Fiona L., Nott, Louise M., Jefford, Michael, Chantrill, Lorraine A., Pavlakis, Nick

Controversies in the management of gastrointestinal stromal tumors

- Yip, Desmond, Zalcberg, John, Ackland, Stephen, Barbour, Andrew P., Desai, Jayesh, Fox, Stephen, Kotasek, Dusan, Mcarthur, Grant, Smithers, B. Mark

KRAS mutation testing of metastatic colorectal cancer in Australia: where are we at?

- Scott, Rodney J., Fox, Stephen B., Byron, Keith, Rudzki, Barney, Waring, Paul, Iacopetta, Barry, Desai, Jayesh, Grieu, Fabienne, Amanuel, Benhur, Garrett, Kerryn, Harraway, James, Cheetham, Glenice, Pattle, Neville, Haddad, Afaf

  • 1
  • Disclaimer
  • Privacy
  • Copyright
  • Contact
  • Deposit